相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
Daniel Tobias Michaeli et al.
CARDIOVASCULAR DRUGS AND THERAPY (2023)
Incremental net benefit of lipid-lowering therapy with PCSK9 inhibitors: a systematic review and meta-analysis of cost-utility studies
Bhavani Shankara Bagepally et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
Daniel Tobias Michaeli et al.
INVESTIGATIONAL NEW DRUGS (2022)
Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland
Daniel Tobias Michaeli et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2022)
The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction
Zanfina Ademi et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2021)
Ethnic inequalities in health-related quality of life among older adults in England: secondary analysis of a national cross-sectional survey
Ruth Elizabeth Watkinson et al.
LANCET PUBLIC HEALTH (2021)
Dose-Dependent Risk Reduction for Myocardial Infarction with Eicosapentaenoic Acid: a Meta-analysis and Meta-regression Including the STRENGTH Trial
Philip Sarajlic et al.
CARDIOVASCULAR DRUGS AND THERAPY (2021)
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)
Frank L. J. Visseren et al.
EUROPEAN HEART JOURNAL (2021)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
European Society of Cardiology: Cardiovascular Disease Statistics 2019
Adam Timmis et al.
EUROPEAN HEART JOURNAL (2020)
Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review
Samad Azari et al.
HEART FAILURE REVIEWS (2020)
COST-EFFECTIVENESS OF ICOSAPENT ETHYL IN US REDUCE-IT PATIENTS
William S. Weintraub et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes The ODYSSEY OUTCOMES Trial
Deepak L. Bhatt et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness
Clara Marquina et al.
PHARMACOECONOMICS (2020)
Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure
Odette S. Reifsnider et al.
ESC HEART FAILURE (2020)
PCV55 Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada.
J. Lachaine et al.
VALUE IN HEALTH (2020)
The cost-effectiveness of omega-3 polyunsaturated fatty acids - The Australian healthcare perspective
Lan Gao et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2019)
Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease
Gregg C. Fonarow et al.
JAMA CARDIOLOGY (2019)
FISHing for the Miracle of Eicosapentaenoic Acid
John J. P. Kastelein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Are PCSK9 Inhibitors Cost Effective?
Max J. Korman et al.
PHARMACOECONOMICS (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines
Dylan L. Steen et al.
BMJ OPEN (2017)
Pleiotropic Effects of Statins on the Cardiovascular System
Adam Oesterle et al.
CIRCULATION RESEARCH (2017)
Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry
Robert Klempfner et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2016)
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
Dhruv S. Kazi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry
Robert Klempfner et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2016)
Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK
Mark D. Danese et al.
BMJ OPEN (2016)
The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84)
M. L. Alva et al.
DIABETIC MEDICINE (2015)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Martin J. Landray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Impact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction A VALIANT Study (Valsartan In Acute Myocardial Infarction)
Eldrin F. Lewis et al.
JACC-HEART FAILURE (2014)
Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy A Meta-analysis
David Preiss et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis
Deepak L. Bhatt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.
Lukasz Januszkiewicz
KARDIOLOGIA POLSKA (2010)
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Henry N. Ginsberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised openlabel, blinded endpoint analysis
Mitsuhiro Yokoyama et al.
LANCET (2007)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
分享论文
